PDCD1 and neoplasm: Therefore, by inhibiting PD-1 or CTLA4 checkpoints or simultaneously inhibiting PD-1 or CTLA4 checkpoints, tumor-specific T cells can be expanded and stimulated to perform anti-tumor functions (32).